Volume 33, Issue 8 (November 2022)
Studies in Medical Sciences 2022, 33(8): 588-595 |
Back to browse issues page
Research code: 111111
Ethics code: 111111
Clinical trials code: 1111111
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Salehi M, Nazarbaghi S, Gholinejad Z, Taghizadeh A. Escitalopram Improves Cognition Function in the Ischemic Stroke Patients. Studies in Medical Sciences 2022; 33 (8) :588-595
URL: http://umj.umsu.ac.ir/article-1-5871-en.html
URL: http://umj.umsu.ac.ir/article-1-5871-en.html
Department of Medical Laboratory Science, Urmia Branch, Islamic Azad University, Urmia, Iran (Corresponding Author) , ghzafar@yahoo.com
Abstract: (2648 Views)
Background & Aims: Cognition impairment is a common manifestation of ischemic stroke patients. The cognition function is modulated by serotonin levels in the brain. The serotonin levels of brain are changed during ischemic stroke. Therefore, we hypothesis that intervention in serotonin reuptake may improve the cognition function in the patients. We evaluated and compared the effect of escitalopram and fluoxetine on ischemic stroke patients.
Materials & Methods: A hundred patients whose ischemic stroke was confirmed by neurologist were enrolled in this interventional study at Imam Khomeini Hospital, Urmia, Iran. All treatments and interventions performed based on a standard approach. The first group received escitalopram(10 mgd/day) as an adjuvant treatment and second group received fluoxetine (10 mgd/day). The cognition function of the patients was measured by Dementia Rating Scale (DRS) in the 5th and 95th days after final diagnosis. Statistical analysis was carried out using IBM SPSS Statistics software version 23.
Results: In this study about 54.1% of patients were female and the rest 45.9% were male. Gender and smoking had no influence on cognition function. There was no difference in the cognition function of the patients with posterior and anterior circulation impairment. Our finding showed escitalopram but not fluoxetine improved the cognition function significantly (p=0.032). Age and creatinine levels had a significant correlation with cognition function before(DRS1) and after (DRS2) treatment and with their difference(DRS2-DRS1). While serum urea levels were correlated with the difference of DRS before and after treatment ( Pearson correlation, -.318, -.397 and P= 0.026, 0.005 respectively)
Conclusion: The results of this study recommends that escitalopram can be used as an adjuvant medicine to improve the cognition function in the ischemic stroke patients. The creatinine and urea levels may be a good biomarker to prescribe escitalopram in the ischemic stroke patients.
Materials & Methods: A hundred patients whose ischemic stroke was confirmed by neurologist were enrolled in this interventional study at Imam Khomeini Hospital, Urmia, Iran. All treatments and interventions performed based on a standard approach. The first group received escitalopram(10 mgd/day) as an adjuvant treatment and second group received fluoxetine (10 mgd/day). The cognition function of the patients was measured by Dementia Rating Scale (DRS) in the 5th and 95th days after final diagnosis. Statistical analysis was carried out using IBM SPSS Statistics software version 23.
Results: In this study about 54.1% of patients were female and the rest 45.9% were male. Gender and smoking had no influence on cognition function. There was no difference in the cognition function of the patients with posterior and anterior circulation impairment. Our finding showed escitalopram but not fluoxetine improved the cognition function significantly (p=0.032). Age and creatinine levels had a significant correlation with cognition function before(DRS1) and after (DRS2) treatment and with their difference(DRS2-DRS1). While serum urea levels were correlated with the difference of DRS before and after treatment ( Pearson correlation, -.318, -.397 and P= 0.026, 0.005 respectively)
Conclusion: The results of this study recommends that escitalopram can be used as an adjuvant medicine to improve the cognition function in the ischemic stroke patients. The creatinine and urea levels may be a good biomarker to prescribe escitalopram in the ischemic stroke patients.
Type of Study: Clinical trials |
Subject:
Neuroscience
References
1. Phipps MS, Cronin CA. Management of acute ischemic stroke. Br Med J 2020;368. [DOI:10.1136/bmj.l6983] [PMID]
2. Riepe MW, Riss S, Bittner D, Huber R. Screening for cognitive impairment in patients with acute stroke. Dement Geriatr Cogn Disord 2004;17(1-2):49-53. [DOI:10.1159/000074082] [PMID]
3. Farokhi-Sisakht F, Farhoudi M, Sadigh-Eteghad S, Mahmoudi J, Mohaddes G. Cognitive Rehabilitation Improves Ischemic Stroke-Induced Cognitive Impairment: Role of Growth Factors. J Stroke Cerebrovasc Dis 2019;28(10):104299. [DOI:10.1016/j.jstrokecerebrovasdis.2019.07.015] [PMID]
4. Sun J-H, Tan L, Yu J-T. Post-stroke cognitive impairment: epidemiology, mechanisms and management. Ann Trans Med 2014;2(8):80-. [PMCID]
5. Ma ZY, Wu YY, Cui HY, Yao GY, Bian H. Factors Influencing Post-Stroke Cognitive Impairment in Patients with Type 2 Diabetes Mellitus. Clin Interv Aging 2022:653-64. [DOI:10.2147/CIA.S355242] [PMID] [PMCID]
6. Ahmed T, Braidy N. From oxidative stress to cognitive decline-towards novel therapeutic approaches. Front Mol Neurosci 2021;14:46. [DOI:10.3389/fnmol.2021.650498] [PMID] [PMCID]
7. Berends H, Nijlant J, Movig K, Van Putten M, Jannink M, IJzerman MJ. The clinical use of drugs influencing neurotransmitters in the brain to promote motor recovery after stroke; a Cochrane systematic review. Eur J Phys Rehabil Med 2009;45(4):621-30. [Google Scholar]
8. Bacqué-Cazenave J, Bharatiya R, Barrière G, Delbecque J-P, Bouguiyoud N, Di Giovanni G, et al. Serotonin in Animal Cognition and Behavior. Int J Mol Sci 2020;21(5):1649. [DOI:10.3390/ijms21051649] [PMID] [PMCID]
9. Cowen P, Sherwood AC. The role of serotonin in cognitive function: evidence from recent studies and implications for understanding depression. J Psychopharmacol 2013;27(7):575-83. [DOI:10.1177/0269881113482531] [PMID]
10. Damsbo AG, Kraglund KL, Buttenschøn HN, Johnsen SP, Andersen G, Mortensen JK. Serotonergic Regulation and Cognition after Stroke: The Role of Antidepressant Treatment and Genetic Variation. Cerebrovasc Dis 2019;47(1-2):72-9. [DOI:10.1159/000498911] [PMID]
11. Mead GE, Hsieh C-F, Lee R, Kutlubaev M, Claxton A, Hankey GJ, et al. Selective serotonin reuptake inhibitors for stroke recovery: a systematic review and meta-analysis. Stroke 2013;44(3):844-50. [DOI:10.1161/STROKEAHA.112.673947] [PMID]
12. Mead GE, Hsieh C-F, Hackett M. Selective serotonin reuptake inhibitors for stroke recovery. JAMA 2013;310(10):1066-7. [DOI:10.1001/jama.2013.107828] [PMID]
13. Siepmann T, Penzlin AI, Kepplinger J, Illigens BMW, Weidner K, Reichmann H, et al. Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence. Brain Behav 2015;5(10):e00373. [DOI:10.1002/brb3.373] [PMID] [PMCID]
14. Hillhouse TM, Porter JH. A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol 2015;23(1):1. [DOI:10.1037/a0038550] [PMID] [PMCID]
15. Waugh J, Goa KL. Escitalopram. CNS Drugs 2003;17:343-62. [DOI:10.2165/00023210-200317050-00004] [PMID]
16. Benfield P, Heel RC, Lewis SP. Fluoxetine. Drugs 1986;32(6):481-508. [DOI:10.2165/00003495-198632060-00002] [PMID]
17. Azorin JM, Llorca PM, Despiegel N, Verpillat P. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder]. Encephale 2004;30(2):158-66. [DOI:10.1016/S0013-7006(04)95427-9] [PMID]
18. Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 2007;46(4):281-90. [DOI:10.2165/00003088-200746040-00002] [PMID]
19. Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994;26(3):201-14. [DOI:10.2165/00003088-199426030-00004] [PMID]
20. Sanchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike? Int Clin Psychopharmacol 2014;29(4):185-96. [DOI:10.1097/YIC.0000000000000023] [PMID] [PMCID]
21. Culpepper L. Escitalopram: A New SSRI for the Treatment of Depression in Primary Care. Prim Care Companion J Clin Psychiatry 2002;4(6):209-14. [DOI:10.4088/PCC.v04n0601] [PMID] [PMCID]
22. Salehnia F, Gholinejad Z, Nazarbaghi S, Rasmi Y, Nikpour MRA, editors. The Gender Difference of Routine Laboratory Tests Performance in Prediction of Early Mortality in Ischemic Stroke Patients. Yeni Symposium; 2018. [DOI:10.5455/NYS.20180111022148]
23. Manning CA, Ducharme JK. Dementia syndromes in the older adult. Handbook of assessment in clinical gerontology: Elsevier; 2010. p. 155-78. [DOI:10.1016/B978-0-12-374961-1.10006-5] [PMID]
24. Mao Px, Tang Yl, Jiang F, Shu L, Gu X, Li M, et al. Escitalopram in major depressive disorder: a multicenter, randomized, double‐blind, fixed‐dose, parallel trial in a Chinese population. Depress Anxiety 2008;25(1):46-54. [DOI:10.1002/da.20222] [PMID]
25. Jorge RE, Acion L, Moser D, Adams HP, Robinson RG. Escitalopram and enhancement of cognitive recovery following stroke. Arch Gen Psychiatry 2010;67(2):187-96. [DOI:10.1001/archgenpsychiatry.2009.185] [PMID] [PMCID]
26. Zhong H, Haddjeri N, Sánchez C. Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter-a review of current understanding of its mechanism of action. Psychopharmacology (Berl) 2012;219(1):1-13. [DOI:10.1007/s00213-011-2463-5] [PMID]
27. Kurella Tamura M, Wadley V, Yaffe K, McClure LA, Howard G, Go R, et al. Kidney function and cognitive impairment in US adults: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Am J Kidney Dis 2008;52(2):227-34. [DOI:10.1053/j.ajkd.2008.05.004] [PMID] [PMCID]
28. Zurru MC, Alonzo C, Brescacin L, Villarroel V, Orzuza G, Camera L, et al. Abstract WP447: Renal Failure Is Associated With Cognitive Impairment In Ischemic Stroke Patients. Am Heart Assoc 2013. [DOI:10.1161/str.44.suppl_1.AWP447]
29. Saberi A, Monfared A, Sobhani A-r, Atrkar-Roushan Z, Rezaei S, Sobhani B, et al. Cognitive impairment and its associated factors in patients undergoing hemodialysis: a cross sectional study. Caspian J Neur Sci 2017;3(3):118-27. [DOI:10.18869/acadpub.cjns.3.10.118]
30. Miglinas M, Cesniene U, Janusaite MM, Vinikovas A. Cerebrovascular Disease and Cognition in Chronic Kidney Disease Patients. Front Cardiovas Med 2020;7:96-. [DOI:10.3389/fcvm.2020.00096] [PMID] [PMCID]
31. Lozano R, Marín R, Santacruz M-J, Frutos A-J. Blood urea levels associated to antidepressant drug treatment: Role of nitrogen and nitric oxide. Indian J Psychiatry 2019;61(3):314-5. [DOI:10.4103/psychiatry.IndianJPsychiatry_141_10] [PMID] [PMCID]
32. Fan M, Gao X, Li L, Ren Z, Lui LMW, McIntyre RS, et al. The Association Between Concentrations of Arginine, Ornithine, Citrulline and Major Depressive Disorder: A Meta-Analysis. Front Psychiat 2021;12. [DOI:10.3389/fpsyt.2021.686973] [PMID] [PMCID]
33. Asadollahi M, Ramezani M, Khanmoradi Z, Karimialavijeh E. The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial. Clin Rehabil 2018;32(8):1069-75. [DOI:10.1177/0269215518777791] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
